/ Lupin Gets USFDA Nod For Generic Ortho-Cyclen 28 Tablets ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Thursday, 3 November 2016

Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for Norgestimate and Ethinyl Estradiol Tablets USP, 0.25 mg/0.035 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Janssen Pharmaceuticals, Inc.’s OrthoCyclen 28 Tablets (Norgestimate/Ethinyl Estradiol). The approved product will be manufactured at Lupin’s Pithampur facility.

Lupin's Norgestimate and Ethinyl Estradiol Tablets USP, 0.25 mg/0.035 mg are the AB rated generic equivalent of Janssen Pharmaceuticals, Inc.’s Ortho-Cyclen 28 Tablets (Norgestimate/Ethinyl Estradiol). It is indicated for use by females of reproductive potential to prevent pregnancy. Ortho-Cyclen Tablets had US sales of USD 178.2 million (IMS MAT June 2016).

Lupin Ltd is currently trading at Rs 1478, down by Rs 17.5 or 1.17% from its previous closing of Rs 1495.5 on the BSE. The scrip opened at Rs 1495 and has touched a high and low of Rs 1501.5 and Rs 1476.2 respectively. So far 289628 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 67483.39 crore.

The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 1911.55 on 09-Feb-2016 and a 52 week low of Rs 1294.05 on 29-Mar-2016. Last one week high and low of the scrip stood at Rs 1543 and Rs 1475.25 respectively.

The promoters holding in the company stood at 46.74 % while Institutions and Non-Institutions held 41.85 % and 11.41 % respectively. The stock is currently trading below its 200 DMA.
For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6554125 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717